Close Menu

NanoString

Merck is hoping NanoString's multiplex platform can support gene expression signatures that will better predict which patients will respond to checkpoint inhibitors like its Keytruda.

The planned instrument will help provide spatial information on both protein and RNA in tumor samples and will be powered by nCounter technology.

Agendia is launching a patient access program to position MammaPrint in clinics, while other test makers are taking a wait-and-see approach.

The gene expression assay, which targets 18 markers, is being used by Merck in three new Phase III clinical trials to expand the indication for Keytruda.

Noridian said it has identified new data that will "significantly impact" its proposed policy on biomarker tests for guiding adjuvant chemotherapy decisions.

Pages